Syncona sets its sights on a gene therapy turnaround
But, with Applied Genetic Technologies Corporation, can lightning strike a third time?
Krystal shines in epidermolysis bullosa
Look out Amryt: Krystal’s topical gene therapy is gaining ground.
Epidermolysis bullosa gene therapies wait in the wings
Amryt marches ahead, but gene therapies from Krystal, Abeona and Castle Creek are heading towards data readouts.
Plenty of choice remains for buyers of gene therapy
Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
Gene therapy clinical holds take centre stage
An analysis of company disclosures reveals a sharp rise in US FDA-imposed halts on clinical work involving gene therapies.
Krystal plays down dropout to claim a mid-stage win
Despite concerns about a missing patient, results from a tiny trial in epidermolysis bullosa boosted Krystal Biotech’s stock by 41%.
Fibrocell gets a reality check
Promising data with Fibrocell’s epidermolysis bullosa gene therapy send the company down as funding worries kick in.
